These results show that the dual targeting of HDAC and RXR by DW22 can reverse CDDP resistance in NSCLC, and this reversal was dependent on the HDAC/RXR/HtrA1 signaling axis. This evidence concerns the gene HTRA1 and non-small cell lung carcinoma.